New Drug Approvals Archive

Get news by email or subscribe to our news feeds.

January 2009

January 7

AllerNaze (triamcinolone acetonide) Nasal Spray - formerly AllerNase

Date of Approval: January 7, 2009
Company: Collegium Pharmaceutical, Inc.
Treatment for: Allergic Rhinitis

AllerNaze, formerly Tri-Nasal (triamcinolone acetonide, USP) is a reformulated aqueous intranasal steroid nasal spray indicated for the once daily treatment of nasal symptoms associated with both seasonal and perennial allergic rhinitis in adults and children twelve years of age and older.

AllerNaze (triamcinolone acetonide) FDA Approval History

January 9

Zingo (lidocaine hydrochloride monohydrate)

Patient Population Altered: January 8, 2009

Zingo (lidocaine hydrochloride monohydrate) FDA Approval History

January 14

Savella (milnacipran)

Date of Approval: January 14, 2009
Company: Forest Laboratories, Inc. and Cypress Bioscience, Inc.
Treatment for: Fibromyalgia

Savella (milnacipran) is a selective serotonin and norepinephrine reuptake inhibitor indicated for the management of fibromyalgia.

Savella (milnacipran) FDA Approval History

January 16

RiaSTAP (Fibrinogen Concentrate (Human))

Date of Approval: January 16, 2009
Company: CSL Behring
Treatment for: Congenital Fibrinogen Deficiency

RiaSTAP (Fibrinogen Concentrate (Human)) is lyophilized fibrinogen for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

RiaSTAP (Fibrinogen Concentrate (Human)) FDA Approval History

January 27

Gelnique (oxybutynin hydrochloride) Topical Gel - formerly OTG

Date of Approval: January 27, 2009
Company: Watson Pharmaceuticals, Inc.
Treatment for: Overactive Bladder

Gelnique (oxybutynin chloride) Gel is a transdermal antispasmodic which is applied to the skin once daily for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.

Gelnique (oxybutynin hydrochloride) FDA Approval History

January 30

Kapidex (dexlansoprazole) Delayed Release Capsules - formerly TAK-390MR

Date of Approval: January 30, 2009
Company: Takeda Pharmaceutical Company Limited
Treatment for: Erosive Esophagitis, Gastroesophageal Reflux Disease

Kapidex (dexlansoprazole) is a proton pump inhibitor with a novel delivery system approved for the treatment of erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).

Kapidex (dexlansoprazole) FDA Approval History

January 23

Vectical (calcitriol) Ointment

Date of Approval: January 23, 2009
Company: Galderma Laboratories, L.P.
Treatment for: Psoriasis

Vectical Ointment is a Vitamin D analog indicated for the topical treatment of mild to moderate plaque psoriasis in adults 18 years and older.

Vectical (calcitriol) FDA Approval History

Hide
(web5)